Methods and Acellular Compositions For Treating Inflammatory Disorders
AssigneeBiomet Biologics, LLC
InventorsJennifer E. WOODELL-MAY, Joel C. HIGGINS, Michael D. LEACH, Krista O'SHAUGHNESSEY
Life of this patent
Estimating the term…
Abstract
Acellular compositions for treating inflammation, comprising two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII. Components of the acellular compositions may be derived from biologic materials, such as blood clots and urine. Components may also be obtained from cell cultures.
Claims29
A substantially acellular anti-inflammatory cytokine composition comprising the following components:
- (a) interleukin-1 receptor angagonist (IL-1ra);
- and
- (b) soluble tumor necrosis factor receptor I;
- wherein at least one of the components is derived from urine, clotted blood, or tissue culture.
A substantially acellular composition for the treatment of a disorder mediated by IL-1 comprising the following components:
- (a) at least about 10,000 pg/ml IL1-ra;
- (b) at least about 1,200 pg/ml sTNF-RI;
- and
- (c) a protein selected from the group consisting of sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-131, and sIL-1RII, and mixtures thereof, wherein the protein has a concentration in the composition greater than the concentration of the protein in normal blood;
- and
- wherein at least one of the components is derived from urine, clotted blood, or tissue culture.
A method for making an acellular composition for the treatment of a disorder mediated by IL-1 comprising:
- (a) culturing, in a growth medium, cells that produce IL-1ra;
- (b) isolating the medium;
- and
- (c) freeze drying the composition.
Dependencies are inferred from the claim text.